U.S. Leads The Overall Facial Injectable Market

LogoGrowing popularity of minimally invasive cosmetic surgeries and increasing disposable income has led to substantial growth in the overall cosmetic procedures market. Facial injectable are generally used for skin rejuvenation, reduction or elimination of dark spots and wrinkles, and lip enhancement. The market for facial injectables has been broadly segmented as follows:

  • Botulinum Toxin
  • Hyaluronic Acid
  • Collagen
  • Polymers and Particles
  • Dermal Fillers

Hyaluronic acid and poly-L-lactic acid (PLLA) are commonly used long lasting facial injectable products which are reported to last from 10 months to 15 months depending on injection site. Restylane (Gladrma) and Juvederm (Allergan) are most popular hyaluronic acid facial injectable brands worldwide. Botulinum toxin marketed under brand names Botox (Allergan) and Dysport (Gladerma) is also one of the long standing products in the market. According to The American Academy of Facial Cosmetics, Botulinum toxin procedures for facial rejuvenation are increasing at a rate of about 4.5% annually in the U.S. Furthermore, statistics published by the American Society of Plastic Surgeons states that between 2013 and 2014, hyaluronic acid (HA) filler treatments had increased by over 8%.

Request Free Report Sample@ http://www.sa-brc.com/Global-Facial-Injectable-Market-Assessment–Forecast-2017-2021/up43

The global facial injectables market is highly competitive, and dominated by few global players. U.S. leads the overall facial injectable market; however the market is rapidly growing in South-East Asian countries owing to increasing trend for medical tourism. In the recent past there has been a surge of counterfeit products circulating in the Asian market. In 2013, ShanghaiDaily published that some patients had approached physicians with complaints of swollen face after using Botox products purchased online at substantially lower costs. In China, Hongli (Lanzhou Institute of Biological Products) and Botox (Allergan) are the only approved botulinum toxin brands. To tap lucrative market opportunity in the facial injectables market, various fake treatment centers have also emerged in this region.

In October 2013, Allergan announced that Juvederm Voluma XC was approved in the U.S. as the first and only dermal filler for deep injection to temporarily correct age-related volume loss in the cheek area in adults over the age of 21. Cosmetic Botox accounted for 15% share in the company’s revenue in 2013. In 2014, Gladerma (Nestle S.A.) announced that it entered into an agreement with Valeant Pharmaceuticals International, Inc. to gain full commercialization rights for Restylane, Perlane, Emervel, Sculptra and Dysport for use in aesthetic dermatology in the U.S. and Canada. These events have changed the global facial injectable market place. Zyderm, Sculptra, Captique, Hylaform, Artefill are other brands competing in the market.

Request For TOC@ http://www.sa-brc.com/Global-Facial-Injectable-Market-Assessment–Forecast-2016—2020/upcomingdetail43

NOTE: This report is currently under research and will be made available to clients on request.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s